How Patient Reporters Identify Adverse Drug ReactionsA Qualitative Study of Reporting via the UK Yellow Card Scheme

被引：0
|
作者：
Janet Krska
Claire Anderson
Elizabeth Murphy
Anthony J. Avery
机构：
[1] Liverpool John Moores University,School of Pharmacy and Biomolecular Sciences
[2] University of Nottingham,Division of Social Research in Medicines and Health, School of Pharmacy
[3] University of Leicester -Attenborough,School of Community Health Sciences, Queen’s Medical Centre
[4] University of Nottingham,undefined
来源：
Drug Safety | 2011年 / 34卷
关键词：
Indapamide; Educational Qualification; Temporal Association; Patient Information Leaflet; Yellow Card Scheme;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Direct reporting of suspected adverse drug reactions (ADRs) to authorities is increasing, but questions remain about how patients identify suspected ADRs and their ability to distinguish between ADRs and other symptoms.
引用
收藏
页码：429 / 436
页数：7
相关论文
共 27 条
  • [1] How Patient Reporters Identify Adverse Drug Reactions A Qualitative Study of Reporting via the UK Yellow Card Scheme
    Krska, Janet
    Anderson, Claire
    Murphy, Elizabeth
    Avery, Anthony J.
    [J]. DRUG SAFETY, 2011, 34 (05) : 429 - 436
  • [2] The Views of Reporters to the UK Yellow Card Scheme on the Importance of Direct Patient Reporting
    Krska, Janet
    Taylor, Julia
    Avery, Anthony J.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S180 - S181
  • [3] Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme
    O'Donovan, Bernadine
    Rodgers, Ruth M.
    Cox, Anthony R.
    Krska, Janet
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (07) : 3434 - 3446
  • [4] Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys
    Avery, A. J.
    Anderson, C.
    Bond, C. M.
    Fortnum, H.
    Gifford, A.
    Hannaford, P. C.
    Hazell, L.
    Krska, J.
    Lee, A. J.
    McLernon, D. J.
    Murphy, E.
    Shakir, S.
    Watson, M. C.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2011, 15 (20) : 1 - +
  • [5] The yellow card scheme: Evaluation of patient reporting of suspected adverse drug reactions
    Ekins-Daukes, S.
    Irvine, D.
    Wise, L.
    Fiddes, S.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S105 - S105
  • [6] The Yellow Card Scheme for reporting adverse drug reactions (ADRs) by patients in the UK will complement, not replace, the Yellow Card reports
    [J]. Reactions Weekly, 2006, 1109 (1) : 3 - 3
  • [7] The Yellow Card Scheme: Patient Reporting of Adverse Drug Reactions and Signals they have Generated
    Foy, M.
    Gandhi, S.
    Suri, S.
    Cumber, S.
    Jadeja, M. M.
    [J]. DRUG SAFETY, 2011, 34 (10) : 903 - 903
  • [8] Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions
    Bracchi, Robert C.
    Tseliou, Foteini
    Copeland, Lauren
    Routledge, Philip A.
    Thomas, Alison
    Woods, Fiona
    Adams, Alana
    Walker, Jenna
    Jadeja, Mitul
    Atkinson, Mark D.
    Ashfield-Watt, Pauline
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (08) : 3344 - 3348
  • [9] Assessing the usability of methods of public reporting of adverse drug reactions to the UK Yellow Card Scheme
    Anderson, Claire
    Gifford, Alison
    Avery, Anthony
    Fortnum, Heather
    Murphy, Elizabeth
    Krska, Janet
    Bond, Christine
    [J]. HEALTH EXPECTATIONS, 2012, 15 (04) : 433 - 440
  • [10] The Yellow Card Scheme: Experience of Patient Reporting of Adverse Drug Reaction Since Nationwide Launch
    Barrow, P. L.
    Foy, M.
    Gandhi, S.
    O'Keefe, V.
    King, C.
    Webb, R.
    [J]. DRUG SAFETY, 2009, 32 (10) : 968 - 968
123